DRIVESHAFT : Darunavir/Ritonavir In Virologically-suppressed Experienced Subjects Halving an Antiretroviral by Finetuning Therapy - A Phase IV Randomized, Open-Label Study to Evaluate in HIV-1 Infected , Virologically-suppressed Patients on Regimens With Darunavir 600mg/ Ritonavir 100mg Twice-daily Switching to Darunavir 800mg/ Ritonavir 100mg Once-daily Versus Continuing Darunavir 600mg/ Ritonavir 100mg Twice-daily Containing Regimens.

Trial Profile

DRIVESHAFT : Darunavir/Ritonavir In Virologically-suppressed Experienced Subjects Halving an Antiretroviral by Finetuning Therapy - A Phase IV Randomized, Open-Label Study to Evaluate in HIV-1 Infected , Virologically-suppressed Patients on Regimens With Darunavir 600mg/ Ritonavir 100mg Twice-daily Switching to Darunavir 800mg/ Ritonavir 100mg Once-daily Versus Continuing Darunavir 600mg/ Ritonavir 100mg Twice-daily Containing Regimens.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Darunavir (Primary) ; Antiretrovirals; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DRIVESHAFT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Apr 2015 Status changed from active, no longer recruiting to completed a per ClinicalTrials.gov record.
    • 23 Mar 2015 According to the the ClinicalTrials.gov record, planned end date changed from 1 Jun 2014 to 1 May 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top